#USA #New York #Class Action #MoonLake #MLTX

Investors Targeted by MoonLake Immunotherapeutics Class Action

Background

Levi & Korsinsky, LLP has recently announced a class action lawsuit aimed at investors of MoonLake Immunotherapeutics (NASDAQ: MLTX). This action seeks to assist those who have suffered financial losses purportedly due to securities fraud linked to the company's misleading statements about its drug candidates, particularly SLK. Between March 10, 2024, and September 29, 2025, alleged misrepresentations have left many investors at a significant financial disadvantage.

Nature of the Allegations

The class action presents several serious allegations against MoonLake Immunotherapeutics. Notably, it claims that the company's management misrepresented the potential of SLK, its flagship drug candidate, which shares molecular targets with BIMZELX, a drug whose structure differs significantly. The lawsuit purports that:

• - The company's claims about SLK's unique Nanobody structure conferring superior clinical benefits were unfounded.
• - Asserted advantages regarding SLK's ability to penetrate tissues effectively did not translate into actual clinical efficacy.
• - The company's public communications failed to offer a reasonable basis for its optimistic statements regarding SLK's performance compared to traditional monoclonal antibodies.

These allegations highlight how investors were led to believe in a product's superiority that may not exist, resulting in significant investment losses.

What Investors Need to Know

If you have experienced financial losses as a result of these alleged misrepresentations during the stated time frame, you may have the opportunity to be part of the class action lawsuit. The deadline to request appointment as a lead plaintiff is December 15, 2025. However, it’s essential to note that participation in the recovery process doesn't necessitate serving as a lead plaintiff, meaning more investors can engage without additional obligations.

Cost-Free Participation

Participation in the class action suit is at no cost for class members. It means reimbursable costs associated with legal representation will not be charged upfront to investors, making it a low-risk opportunity to recover expenses incurred due to the alleged securities fraud. Those interested in exploring this option can contact Levi & Korsinsky directly for further details.

Why Choose Levi & Korsinsky

For over two decades, Levi & Korsinsky has established itself as a leader in securities litigation, successfully securing hundreds of millions for aggrieved shareholders. The firm is recognized in the industry, appearing in the ISS Securities Class Action Services' Top 50 Report as one of the leading securities litigation firms in the United States for several consecutive years. With a team of highly experienced professionals dedicated to representing investors, they provide that necessary expertise and support for those navigating complex securities claims.

How to Get Involved

If you believe you have been affected by MoonLake’s alleged securities fraud and wish to join the suit, you can reach out to Levi & Korsinsky for assistance. Potential investors are encouraged to fill out the submission form linked below, or can contact attorney Joseph E. Levi via email or phone for more information.

Class Action Submission Form

For personal inquiries, individuals may also communicate directly:

• - Email: [email protected]
• - Phone: (212) 363-7500

By taking these steps, investors can explore their options for financial recovery and ensure their voices are heard amidst these substantial allegations.

Conclusion

Now is the time for affected investors to act and possibly regain what they have lost due to MoonLake Immunotherapeutics. Stay informed, get involved, and remember that recovery efforts are underway, provided they take the necessary steps before the approaching deadlines.